Wall Street Radar: Stocks to Watch Next Week
š¼ Volume 93
The Empty Basket
Weāll be straight with you. This week, we barely traded at all.
The tape gave us almost nothing we trusted. Choppy, fast, contradictory. In one session, the leaders were flying, and in the next, they were getting cut open. Records printed and got handed back within forty-eight hours. More than a trillion in value walked out of the loudest corner of the market in a matter of days, then a chunk of it came sprinting back as if nothing had happened. Reading a market like that in real time is a coin flip!
So we made a decision, and not a comfortable one. We went to the cash.
Not all the way into a bunker, but close. Weāve already given back more to this market than weād like this year, and right now weāre running a couple of points behind the Nasdaq. That gap stings. Itās the kind of number that makes you want to force something, to lunge at the next shiny setup just to feel like youāre catching up. That instinct is exactly the one that turns a two percent gap into a ten percent hole. We know, because weāve paid for that lesson before.
This is the part of the job nobody frames for the wall. Portfolio management, done every single day, isnāt a highlight reel of green candles. Itās a lot of weeks like this one, where the smartest thing you can do is refuse to play a hand you canāt read. Weāre still content with where we sit. Weāre not content with how weāve read the last stretch, and we intend to fix that. Both things are true at the same time.
Let us tell you a small story.
A fisherman spent one summer teaching his grandson the trade.
The boy was fast and hungry and wanted a full basket every single day. One grey morning, the whole harbor pushed out early, the water already turning mean, and the boy begged to follow. The old man just kept tying the boat tighter to the dock. āThe fish will be there tomorrow,ā he said. āYou might not.ā The boy sulked in an empty harbor while everyone else chased the catch. That night, the sea came up hard and kept three boats that never made it home. In the morning, the old man untied the ropes, looked at the boy, and said the thing heād remember for the rest of his life. āYesterday, you thought an empty basket meant you lost. It meant youāre still here to fish.ā
Cash is that empty basket.
It isnāt fear, and it isnāt quitting. Itās the decision to still be in business when the water turns friendly again. Every trader learns this eventually.
Surviving the bad tape is the whole game, because you canāt compound a return you already handed back, reaching for a trade that was never really there.
Now, looking into next week, it isnāt all storm clouds.
Underneath the noise, something healthier is taking shape. A lot of newer sectors are holding their ground while the crowded trades come apart. The names that ran too far, too fast, have been pulling back toward their 50-day lines, letting the air out of the excess instead of the whole balloon. Some of the most speculative stories, the ones that went vertical on hope alone, have been cut close to half in a matter of weeks. None of that is pleasant while it happens. All of it is the kind of reset that lets a market rebuild a firmer floor and turn back up.
If itās left alone, that is. The one thing that can break this setup is the thing that keeps breaking every setup lately: a shock nobody has on their chart. A flare-up in the wrong corner of the world, oil jumping on a single headline, a policy surprise landing at the worst possible hour. Weāve had a steady diet of those this year, and any one of them can override the cleanest technical picture in an afternoon.
So we wait. Basket empty, boat tied, eyes on the water. When the market finally shows its hand, we intend to be rested, liquid, and ready to move with size. Until then, patience isnāt sitting still. Itās the position.
Hereās a look at this weekās market health, with a breakdown of index and sector performance.
Weāre currently building the beta version of our app, and itās already live.
It is not a generic solution for every market participant, but a platform built specifically for swing trading, momentum strategies, and short to medium-term investing.
You can already sign up, access the beta, and start using it today.
As previously stated, all paid subscribers will receive full access to the platform at no additional cost.
Latest articles:
Each stock carries a risk badge: ā ļø High | š Medium | š”ļø Low.
Based on volatility, float, technicals, and fundamentals. Size your positions accordingly.
š Free Setup: Make It Count
BFLY: Butterfly Network Inc ā ļø
What they do: A medical technology company that makes handheld ultrasound devices
Why watch? Butterfly Network started life as an ultrasound equipment maker. It is quietly becoming something closer to a semiconductor licensing business with a medical device wrapped around it, and that shift is the whole reason to pay attention.
A quick explanation of the technology helps clarify why this matters. Traditional ultrasound machines use piezoelectric crystals as transducers, tiny components that vibrate when voltage is applied, sending sound waves into the body. When those waves hit an organ, they bounce back, and the crystals capture the returning waves and convert them into the electrical signal that becomes an image on a screen. Butterfly uses the same basic physics but replaces those crystals with silicon transducers built directly onto a microchip, roughly 9,000 of them on a single chip, each one individually controllable. That individual control is what gives the device its flexibility: a single probe can adjust frequency, shape, focus, and aperture on the fly, meaning one handheld unit can perform the job that would otherwise require several different specialized probes. The companyās current device, the iQ3, is FDA authorized for cardiac, abdominal, vascular, gynecological, urological, pulmonary, and several other diagnostic applications. That flexibility, combined with the small form factor, is why the product works in settings where carrying multiple ultrasound machines simply is not practical: primary care offices, ambulances, and rural clinics.
The part of the business that has re-rated the stock recently is the licensing arm. Butterfly has opened its transducer-on-chip platform for other companies to build their own devices on top of, and management has said it is in active discussions with roughly 40 companies about licensing the chip. One of those discussions became public in dramatic fashion. A next-generation full-body scanner was unveiled that produces MRI-quality imaging with zero radiation, scans an entire body in under a minute, and runs at a fraction of the operating cost of an MRI machine. The device works by packing 40 of Butterflyās imaging modules into a single machine, using roughly half a million sensors scanning simultaneously, with no radiation exposure and none of the magnetic safety concerns that come with traditional MRI. The licensing agreement behind that device was disclosed in November 2025 and carries potential payments of up to $74 million over five years. It is a significant validation of the embedded licensing strategy, proving the chip technology can be the foundation for entirely new categories of medical imaging devices that Butterfly itself never has to manufacture.
The underlying financials have been improving steadily alongside the licensing narrative. Q1 revenue came in at $26.5 million, up 25% year over year. Full-year 2026 guidance sits between $117 million and $121 million, implying 20% to 24% growth. The company holds $138 million in cash against an annual cash burn of roughly $23 million, which works out to close to six years of runway at the current spending rate. That runway matters for a company still working toward sustained profitability.
The valuation is the honest risk here. Even assuming Butterfly hits its own 2030 revenue target of $500 million, the current market capitalization already implies the market is pricing in outcomes well beyond that target, presumably driven by continued acceleration in chip licensing revenue. That is a real possibility given the trajectory, but it is a bet on execution several years out, not a statement about where the business sits today.
Technical Outlook: The stock made an extraordinary 60% move following the full-body scanner news, then found support near the $7.00 level a few sessions later. It has since pulled back to retest that same area. This is a speculative name that needs a healthy, risk-on broader market to make sustained new highs, since moves like this tend to compress quickly when overall sentiment sours. The ideal scenario is a hold near $7.00, which also coincides with the rising 20-day EMA. 65min Chart is useful to anticipate a break of the 8.00 level after a double inside day last week.
Why We Donāt Wait for Sunday
Markets donāt move on your schedule. The best low-risk entries donāt announce themselves politely and wait for the weekend newsletter.
They show up when they show up. And if youāre not positioned, you miss them.
Paid members get real-time alerts: exact entries, stops, position sizing, and the thesis behind every trade. The same information we use to manage our own capital.
Free members get just one pick on Sunday.
Does that sound like an edge to you?
Whatās Inside Premium
Free Access to TradeDeck
Premium members get early access to TradeDeck, the trading platform weāre building. The value of the platform alone already exceeds the cost of the subscription.
Watchlist Elite (5-7 Stocks)
Each selection undergoes rigorous financial analysis, technical evaluation, and strategic assessment.
Full Portfolio Transparency
Every position we hold. Entry price. Current P&L. Stop level. Real money, real risk.
Real-Time Trade Alerts (Chat Access)
This is where the edge lives. Exact entries, stops, and position sizing. Real-time. No lag
Quick Picks (5 Names)
Additional setups that just missed our main criteria but are worth watching.
Chat Access
See our thought process in real time. Ask questions. Watch how we manage risk.
The Tools We Actually Use
Member discounts on TC2000, Fiscal.ai, and other platforms. Same tools, better pricing.
What Paid Members Say:
Weāre entrepreneurs first, traders second. Weāve sat in the CEO chair. We know what real execution looks like and how to spot it.
ā¬39/month or 299ā¬/year. Less than one losing trade. Cancel anytime.
Portfolio updates and new positions:
